


6864727




Bone Marrow For Leukaemia Trust
(A company limited by guarantee, without a share capital)

Abridged Financial Statements

for the year ended 31 December 2015





Bone Marrow For Leukaemia Trust
(A company limited by guarantee, without a share capital)
CONTENTS

	Page
Directors' Responsibilities Statement	3
Independent Auditor's Special Report to the Directors	4 - 5
Abridged Balance Sheet	6 - 7
Reconciliation of Members' Funds	8
Cash Flow Statement	9
Notes to the Abridged Financial Statements	10 - 13



Bone Marrow For Leukaemia Trust

(A company limited by guarantee, without a share capital)

DIRECTORS' RESPONSIBILITIES STATEMENT

for the year ended 31 December 2015

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.


Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council and promulgated by the Institute of Chartered Accountants in Ireland. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy and enable them to ensure that the financial statements and directors' report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board



Michael Cronin
Director



Prof Shaun McCann
Director

2 September 2016



INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE DIRECTORS OF BONE MARROW FOR LEUKAEMIA TRUST

pursuant to section 356(1) and 356(2) of the Companies Act 2014

On 2 September 2016 we reported as auditors of Bone Marrow For Leukaemia Trust to the directors of the company on the copy of the abridged financial statements for the year ended 31 December 2015 on pages 6 to 13 and our report was as follows:

'We have examined :

- (i) the abridged financial statements for the year ended 31 December 2015 on pages 6 to 13 which the directors of Bone Marrow For Leukaemia Trust propose to annex to the annual return of the company; and
- (ii) the financial statements to be laid before the Annual General Meeting, which form the basis for those abridged financial statements.

This report is made solely to the company's members, as a body, in accordance with section 356(2) of the Companies Act 2014. Our work has been undertaken so that we might state to the directors those matters we are required to state to them in our report under section 356(2) of the Companies Act 2014 and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the directors for our work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors

It is your responsibility to prepare abridged financial statements which comply with section 352 of the Companies Act 2014. It is our responsibility to form an independent opinion that the directors are entitled under section 352 of the Companies Act 2014 to annex abridged financial statements to the annual return of the company and that those abridged financial statements have been properly prepared pursuant to sections 352 and 353 of that Act and to report our opinion to you.

Basis of opinion

We have carried out the procedures we consider necessary to confirm, by reference to the financial statements, that the company is entitled to annex abridged financial statements to the annual return of the company and that the abridged financial statements are properly prepared. The scope of our work for the purpose of this report does not include examining or dealing with events after the date of our report on the full financial statements.

Opinion

In our opinion the directors are entitled under section 352 of the Companies Act 2014 to annex to the annual return of the company the abridged financial statements and those abridged financial statements have been properly prepared pursuant to the provisions of section 353 of that Act (exemptions available to small companies).'

Other Information

On 2 September 2016 we reported as auditors of Bone Marrow For Leukaemia Trust to the members on the company's financial statements for the year ended 31 December 2015 to be laid before its Annual General Meeting and our report was as follows:

'We have audited the financial statements of Bone Marrow For Leukaemia Trust for the year ended 31st December 2015 which comprise the Income and Expenditure Account, the Balance Sheet, the Reconciliation of Members' Funds, the Cash Flow Statement, the Accounting Policies and the related notes. The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council and promulgated by the Institute of Chartered Accountants in Ireland.

This report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and otherwise comply with the Companies Act 2014. Our responsibility is to audit and express an opinion on the financial statements in accordance with Irish law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practice Board's Ethical Standards for Auditors.

**INDEPENDENT AUDITOR'S SPECIAL REPORT TO THE DIRECTORS
OF BONE MARROW FOR LEUKAEMIA TRUST**
pursuant to section 356(1) and 356(2) of the Companies Act 2014

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the directors; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Directors' Report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

Opinion on financial statements

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2015 and of its results for the year then ended; and
- have been properly prepared in accordance with the relevant financial reporting framework and, in particular, the requirements of the Companies Act 2014.

Matters on which we are required to report by the Companies Act 2014


- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited.
- The financial statements are in agreement with the accounting records.
- In our opinion the information given in the Directors' Report is consistent with the financial statements.

Matters on which we are required to report by exception

We have nothing to report in respect of the provisions in the Companies Act 2014 which require us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by Sections 305 to 312 of the Act are not made.'

for and on behalf of
RYAN & CROWLEY LIMITED
Chartered Accountant & Registered Auditor
Abercorn House
57 Charleston Road
Ranelagh
Dublin 6

We certify that the auditor's report on pages 4 - 5 made pursuant to section 356(1) of the Companies Act 2014 is a true copy of the original.



Michael Cronin
Director



Edward Fleming
Secretary

2 September 2016

.....

.....

Bone Marrow For Leukaemia Trust
(A company limited by guarantee, without a share capital)
ABRIDGED BALANCE SHEET
as at 31 December 2015


	Notes	2015 €	2014 €
Fixed Assets			
Tangible assets		1,951,090	1,958,032
Investments		1,547,462	1,160,600
		<u>3,498,552</u>	<u>3,118,632</u>
Current Assets			
Debtors		82,665	51,971
Cash and cash equivalents		373,129	803,664
		<u>455,794</u>	<u>855,635</u>
Creditors: Amounts falling due within one year		<u>(9,049)</u>	<u>(2,579)</u>
Net Current Assets		<u>446,745</u>	<u>853,056</u>
Total Assets less Current Liabilities		<u>3,945,297</u>	<u>3,971,688</u>
Government grants		<u>(2,545)</u>	<u>(6,354)</u>
Net Assets		<u><u>3,942,752</u></u>	<u><u>3,965,334</u></u>
Reserves			
Income and expenditure account		3,942,752	3,965,334
Equity attributable to owners of the company		<u><u>3,942,752</u></u>	<u><u>3,965,334</u></u>

Bone Marrow For Leukaemia Trust
(A company limited by guarantee, without a share capital)
ABRIDGED BALANCE SHEET
as at 31 December 2015


We, as Directors' of Bone Marrow For Leukaemia Trust, state that -

The company has relied on the specified exemption contained in section 352 Companies Act 2014; the company has done so on the grounds that it is entitled to the benefit of that exemption as a small company and confirm that the abridged Financial Statements have been properly prepared in accordance with section 353 Companies Act 2014.

Approved by the board on 2 September 2016 and signed on its behalf by:



Michael Cronin
Director



Prof Shaun McCann
Director

2 September 2016



Bone Marrow For Leukaemia Trust
 (A company limited by guarantee, without a share capital)
RECONCILIATION OF MEMBERS' FUNDS
 as at 31 December 2015

	Retained surplus	Total
	€	€
At 1 January 2014	3,646,352	3,646,352
Surplus for the year	318,982	318,982
At 31 December 2014	3,965,334	3,965,334
Deficit for the year	(22,582)	(22,582)
At 31 December 2015	3,942,752	3,942,752

Bone Marrow For Leukaemia Trust
(A company limited by guarantee, without a share capital)

CASH FLOW STATEMENT

for the year ended 31 December 2015

	Notes	2015 €	2014 €
Cash flows from operating activities			
(Deficit)/surplus for the year		(22,582)	318,982
Adjustments for:			
Fair value gains and losses		113,138	(160,600)
Interest receivable and similar income		(27,901)	1,873
Depreciation		6,942	7,298
Amortisation of government grants		(3,809)	(3,809)
		<u>65,788</u>	<u>163,744</u>
Movements in working capital:			
Movement in debtors		(30,694)	4,218
Movement in creditors		6,470	(3,194)
		<u>41,564</u>	<u>164,768</u>
Cash flows from investing activities			
Interest received		27,901	(1,873)
Payments to acquire investments		(500,000)	-
		<u>(472,099)</u>	<u>(1,873)</u>
Net cash used in investment activities			
		<u>(430,535)</u>	162,895
Net (decrease)/increase in cash and cash equivalents		(430,535)	162,895
Cash and cash equivalents at beginning of financial year		803,664	640,769
		<u>803,664</u>	<u>640,769</u>
Cash and cash equivalents at end of financial year	7	373,129	803,664
		<u><u>373,129</u></u>	<u><u>803,664</u></u>

.....

Bone Marrow For Leukaemia Trust

(A company limited by guarantee, without a share capital)

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the year ended 31 December 2015

1. GENERAL INFORMATION

Bone Marrow For Leukaemia Trust is a company limited by guarantee incorporated in the Republic of Ireland.

2. ACCOUNTING POLICIES

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 December 2015 have been prepared on the going concern basis and in accordance with generally accepted accounting principles in Ireland and Irish statute comprising the Companies Act 2014 and in accordance with the Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland (FRS 102) issued by the Financial Reporting Council. These are the company's first set of financial statements prepared in accordance with FRS 102 (see note 5 for an explanation of the transition)

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council and promulgated by the Institute of Chartered Accountants in Ireland.

Income

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible fixed assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-	4% Straight line
Fixtures, fittings and equipment	-	15% Straight Line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Investments

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the income and expenditure account in the year in which it is receivable.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.



Bone Marrow For Leukaemia Trust

(A company limited by guarantee, without a share capital)

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

continued

for the year ended 31 December 2015

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable income for the year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income and Expenditure Account.

3. ADOPTION OF FRS 102

This is the first set of financial statements prepared by Bone Marrow For Leukaemia Trust in accordance with accounting standards issued by the Financial Reporting Council, including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"). The company transitioned from previously extant Irish and UK GAAP to FRS 102 as at 1 January 2014.

4. DEPARTURE FROM COMPANIES ACT 2014 PRESENTATION

The directors have elected to present an Income and Expenditure Account instead of a Profit and Loss Account in these financial statements as this company is a not-for-profit entity.



Bone Marrow For Leukaemia Trust

(A company limited by guarantee, without a share capital)

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

continued

for the year ended 31 December 2015

5. RECONCILIATIONS ON TRANSITION TO FRS 102**BALANCE SHEET - ASSETS AND LIABILITIES**

	At 1 January 2014			At 31 December 2014		
	As previously stated	Effect of transition	As restated	As previously stated	Effect of transition	As restated
	€	€	€	€	€	€
Fixed Assets						
Tangible assets	1,965,330	-	1,965,330	1,958,032	-	1,958,032
Financial assets	1,000,000	-	1,000,000	1,160,600	-	1,160,600
	<u>2,965,330</u>	<u>-</u>	<u>2,965,330</u>	<u>3,118,632</u>	<u>-</u>	<u>3,118,632</u>
Current Assets						
Debtors	56,189	-	56,189	51,971	-	51,971
Cash at bank and in hand	640,769	-	640,769	803,664	-	803,664
	<u>696,958</u>	<u>-</u>	<u>696,958</u>	<u>855,635</u>	<u>-</u>	<u>855,635</u>
Creditors: Amounts falling due within one year	<u>(5,773)</u>	<u>-</u>	<u>(5,773)</u>	<u>(2,579)</u>	<u>-</u>	<u>(2,579)</u>
Net Current Assets	<u>691,185</u>	<u>-</u>	<u>691,185</u>	<u>853,056</u>	<u>-</u>	<u>853,056</u>
Total Assets less Current Liabilities	<u>3,656,515</u>	<u>-</u>	<u>3,656,515</u>	<u>3,971,688</u>	<u>-</u>	<u>3,971,688</u>
Government grants	<u>(10,163)</u>	<u>-</u>	<u>(10,163)</u>	<u>(6,354)</u>	<u>-</u>	<u>(6,354)</u>
Net Assets	<u><u>3,646,352</u></u>	<u><u>-</u></u>	<u><u>3,646,352</u></u>	<u><u>3,965,334</u></u>	<u><u>-</u></u>	<u><u>3,965,334</u></u>

Bone Marrow For Leukaemia Trust

(A company limited by guarantee, without a share capital)

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

continued

for the year ended 31 December 2015

5.1. BALANCE SHEET - RESERVES

	At 1 January 2014			At 31 December 2014		
	As previously stated €	Effect of transition €	As restated €	As previously stated €	Effect of transition €	As restated €
Reserves						
Revaluation reserve	-	-	-	160,600	(160,600)	-
Income and expenditure account	3,646,352	-	3,646,352	3,804,734	160,600	3,965,334
Equity attributable to Members of the Company	<u>3,646,352</u>	<u>-</u>	<u>3,646,352</u>	<u>3,965,334</u>	<u>-</u>	<u>3,965,334</u>

5.2. STATEMENT ON PREVIOUS PERIODS

(i) In previous periods the gains on Investments were analysed to the Revaluation Reserve and not the Income and Expenditure Account. In accordance with FRS 102 the gain in 2014 of €160,600 was analysed to the Income and Expenditure Account. The loss on the fair value movement in 2015 of €113,138 was analysed to the Income and Expenditure Account.

6. STATUS

The liability of the members is limited.

Every member of the company undertakes to contribute to the assets of the company in the event of its being wound up while they are members, or within one year thereafter, for the payment of the debts and liabilities of the company contracted before they ceased to be members, and of the costs, charges and expenses of winding up, and for the adjustment of the rights of the contributors among themselves, such amount as may be required, not exceeding € 2.

7. CASH AND CASH EQUIVALENTS

	2015 €	2014 €
Cash and bank balances	170,533	603,049
Cash equivalents	202,596	200,615
	<u>373,129</u>	<u>803,664</u>

8. APPROVAL OF FINANCIAL STATEMENTS

The financial statements were approved and authorised for issue by the board of directors on 2 September 2016.

**INDEPENDENT AUDITOR'S REPORT TO THE DIRECTORS
of Bone Marrow For Leukaemia Trust
pursuant to section 356(2) of the Companies Act 2014**

We have examined:

- (i) the abridged financial statements for the year ended 31 December 2015 on pages 6 to 13 which the directors of Bone Marrow For Leukaemia Trust propose to annex to the annual return of the company ; and
- (ii) the financial statements to be laid before the Annual General Meeting, which form the basis for those abridged financial statements.

This report is made solely to the company's members, as a body, in accordance with section 356(2) of the Companies Act 2014. Our work has been undertaken so that we might state to the directors those matters we are required to state to them in our report under section 356(2) of the Companies Act 2014 and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the directors for our work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors

It is your responsibility to prepare abridged financial statements which comply with the section 352 of the Companies Act 2014. It is our responsibility to form an independent opinion that the directors are entitled under section 352 of the Companies Act 2014 to annex abridged financial statements to the annual return of the company and that those abridged financial statements have been properly prepared pursuant to sections 352 and 353 of that Act and to report our opinion to you.

Basis of opinion

We have carried out the procedures we consider necessary to confirm, by reference to the financial statements, that the company is entitled to annex abridged financial statements to the annual return of the company and that the abridged financial statements are properly prepared. The scope of our work for the purpose of this report does not include examining or dealing with events after the date of our report on the full financial statements.

Opinion

In our opinion the directors are entitled under section 352 of the Companies Act 2014 to annex to the annual return of the company the abridged financial statements and those abridged financial statements have been properly prepared pursuant to the provisions of section 353 of that Act (exemptions available to small companies).'

RYAN & CROWLEY LIMITED

Chartered Accountant & Registered Auditor
Abercorn House
57 Charleston Road
Ranelagh
Dublin 6

2 September 2016

2

